PureTech shows durability of pulmonary fibrosis candidate, plots phase 3 trial
One day after Boehringer Ingelheim presented so-so data from a successful trial of its highly touted idiopathic pulmonary fibrosis (IPF) candidate nerandomilast, PureTech answered with results from an open-label extension study of its IPF hopeful deupirfenidone.
One day after Boehringer Ingelheim presented so-so data from a successful trial of its highly touted idiopathic pulmonary fibrosis (IPF) candidate nerandomilast, PureTech answered with results from an open-label extension study of its IPF hopeful deupirfenidone.
